KR20230083301A - 알파-d-갈락토피라노사이드의 스피로 유도체 - Google Patents
알파-d-갈락토피라노사이드의 스피로 유도체 Download PDFInfo
- Publication number
- KR20230083301A KR20230083301A KR1020237014525A KR20237014525A KR20230083301A KR 20230083301 A KR20230083301 A KR 20230083301A KR 1020237014525 A KR1020237014525 A KR 1020237014525A KR 20237014525 A KR20237014525 A KR 20237014525A KR 20230083301 A KR20230083301 A KR 20230083301A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- pyran
- hydroxymethyl
- triazol
- oxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003003 spiro group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 137
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 7
- -1 cyano, methoxy Chemical group 0.000 claims description 140
- 125000001424 substituent group Chemical group 0.000 claims description 69
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 56
- 229910052757 nitrogen Inorganic materials 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 25
- 230000002265 prevention Effects 0.000 claims description 24
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 206010016654 Fibrosis Diseases 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 208000020832 chronic kidney disease Diseases 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000037765 diseases and disorders Diseases 0.000 claims description 18
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 16
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 230000004761 fibrosis Effects 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 208000019423 liver disease Diseases 0.000 claims description 12
- BHDLTOUYJMTTTM-UHFFFAOYSA-N oxan-3-ol Chemical compound OC1CCCOC1 BHDLTOUYJMTTTM-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 10
- 208000016222 Pancreatic disease Diseases 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052760 oxygen Chemical group 0.000 claims description 8
- 239000001301 oxygen Chemical group 0.000 claims description 8
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 7
- 208000033626 Renal failure acute Diseases 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 201000011040 acute kidney failure Diseases 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 7
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 208000024691 pancreas disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- SRBYGPLICFWXNK-JGOTUQMDSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC3(CC3)CCC3(F)F)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC3(CC3)CCC3(F)F)O)[C@H]2OC)N=N1)=C1F)=C1F SRBYGPLICFWXNK-JGOTUQMDSA-N 0.000 claims description 4
- 208000030533 eye disease Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- GJFJXQKDEPDJDY-JGOTUQMDSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCCCC3)N3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCCCC3)N3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F GJFJXQKDEPDJDY-JGOTUQMDSA-N 0.000 claims description 3
- DMOLOFMNOLBLPR-IFDNJSJMSA-N CC(N(C[C@H]([C@@H]([C@H]1N2N=NC(C(C=CC(C)=C3F)=C3F)=C2)OC)O[C@H](CO)[C@@H]1O)C1)=NC11CCCCC1 Chemical compound CC(N(C[C@H]([C@@H]([C@H]1N2N=NC(C(C=CC(C)=C3F)=C3F)=C2)OC)O[C@H](CO)[C@@H]1O)C1)=NC11CCCCC1 DMOLOFMNOLBLPR-IFDNJSJMSA-N 0.000 claims description 3
- LDHHHUPKPKHVPE-XDOCFNAUSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(Cl)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(Cl)=C2F)=C1 LDHHHUPKPKHVPE-XDOCFNAUSA-N 0.000 claims description 3
- QIHPSASIRKOWCN-JGOTUQMDSA-N CO[C@@H]([C@@H](CN(CC1(CCCCC1)CN1)C1=O)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CN(CC1(CCCCC1)CN1)C1=O)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 QIHPSASIRKOWCN-JGOTUQMDSA-N 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 claims description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- FCTMTYDSWDSLAU-DJCPXJLLSA-N CC(C(F)=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1)=C1F Chemical compound CC(C(F)=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1)=C1F FCTMTYDSWDSLAU-DJCPXJLLSA-N 0.000 claims description 2
- WIUGXAZLDWGAIB-PGMUVVTESA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC3(CC3)CCC3C#N)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC3(CC3)CCC3C#N)O)[C@H]2OC)N=N1)=C1F)=C1F WIUGXAZLDWGAIB-PGMUVVTESA-N 0.000 claims description 2
- ITXJQKRSEARKOQ-DJCPXJLLSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1)=C1F ITXJQKRSEARKOQ-DJCPXJLLSA-N 0.000 claims description 2
- XSCFUEGLPKOXPY-PGEXYDAJSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OC)N=N1)=C1F)=C1F XSCFUEGLPKOXPY-PGEXYDAJSA-N 0.000 claims description 2
- NXCJPDPXBVHRCT-YNGJRPBFSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OCC(O)=O)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CC(C3)=NOC33CCCCC3)O)[C@H]2OCC(O)=O)N=N1)=C1F)=C1F NXCJPDPXBVHRCT-YNGJRPBFSA-N 0.000 claims description 2
- CTOLXZVEAQKBIL-PGEXYDAJSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(C3)C=NC33CCCCC3)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(C3)C=NC33CCCCC3)O)[C@H]2OC)N=N1)=C1F)=C1F CTOLXZVEAQKBIL-PGEXYDAJSA-N 0.000 claims description 2
- HDNAMKIWIBYWJV-JGOTUQMDSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCCCC3)O3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCCCC3)O3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F HDNAMKIWIBYWJV-JGOTUQMDSA-N 0.000 claims description 2
- YBRGYPQDZXTXJD-MLMGXCOMSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCOCC3)O3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CN(CC3(CCOCC3)O3)C3=O)O)[C@H]2OC)N=N1)=C1F)=C1F YBRGYPQDZXTXJD-MLMGXCOMSA-N 0.000 claims description 2
- ISHQTZLTZLRKTG-SRBMLKMVSA-N CC(C=CC(C1=CN([C@H]([C@H]([C@@H](CC(C2)=NOC2(CC2)CCC2(F)F)O[C@@H]2CO)O)[C@H]2O)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@H]([C@H]([C@@H](CC(C2)=NOC2(CC2)CCC2(F)F)O[C@@H]2CO)O)[C@H]2O)N=N1)=C1F)=C1F ISHQTZLTZLRKTG-SRBMLKMVSA-N 0.000 claims description 2
- PDLXOWGSGXDNTC-SRBMLKMVSA-N CC(C=CC(C1=CN([C@H]([C@H]([C@@H](CC(C2)=NOC22CCOCC2)O[C@@H]2CO)O)[C@H]2O)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@H]([C@H]([C@@H](CC(C2)=NOC22CCOCC2)O[C@@H]2CO)O)[C@H]2O)N=N1)=C1F)=C1F PDLXOWGSGXDNTC-SRBMLKMVSA-N 0.000 claims description 2
- NYMYHXASTIYJKQ-PGEXYDAJSA-N CC(O[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1(F)F)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(C)=C2F)=C2F)=C1)=O Chemical compound CC(O[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1(F)F)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(C)=C2F)=C2F)=C1)=O NYMYHXASTIYJKQ-PGEXYDAJSA-N 0.000 claims description 2
- IYSBHEGSVOXPJU-QISNUPPCSA-N CCO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CCO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 IYSBHEGSVOXPJU-QISNUPPCSA-N 0.000 claims description 2
- JVPBTHYMPXEJQK-IFDNJSJMSA-N CNC(CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O Chemical compound CNC(CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O JVPBTHYMPXEJQK-IFDNJSJMSA-N 0.000 claims description 2
- PJAHRPHYVLAEFO-IFDNJSJMSA-N COC(CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O Chemical compound COC(CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O PJAHRPHYVLAEFO-IFDNJSJMSA-N 0.000 claims description 2
- OCUNPGREBQDCJL-JEALBOLUSA-N CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1C#N)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1C#N)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 OCUNPGREBQDCJL-JEALBOLUSA-N 0.000 claims description 2
- DKURKEAKPKUBBB-JEALBOLUSA-N CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1C#N)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1C#N)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 DKURKEAKPKUBBB-JEALBOLUSA-N 0.000 claims description 2
- VRNICCQAZXTHJM-XDOCFNAUSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2Cl)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2Cl)=C1 VRNICCQAZXTHJM-XDOCFNAUSA-N 0.000 claims description 2
- RFBAYRBJXQKTAO-XDOCFNAUSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 RFBAYRBJXQKTAO-XDOCFNAUSA-N 0.000 claims description 2
- RFYQYNTZKCXZHG-JGOTUQMDSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Br)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Br)=C2F)=C2F)=C1 RFYQYNTZKCXZHG-JGOTUQMDSA-N 0.000 claims description 2
- NKHHRRKQVVDECN-JGOTUQMDSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(Cl)=C2F)=C2F)=C1 NKHHRRKQVVDECN-JGOTUQMDSA-N 0.000 claims description 2
- MFCKKWPPNSVBFX-JGOTUQMDSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 MFCKKWPPNSVBFX-JGOTUQMDSA-N 0.000 claims description 2
- QMHADSTWLSZSGI-QISNUPPCSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 QMHADSTWLSZSGI-QISNUPPCSA-N 0.000 claims description 2
- JXEYDRXYGINNSA-MLMGXCOMSA-N CO[C@@H]([C@@H](CC(C1)=NOC11CCOCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC11CCOCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=CC(F)=C2F)=C2F)=C1 JXEYDRXYGINNSA-MLMGXCOMSA-N 0.000 claims description 2
- DKEFKZPBIMPYER-BJKUESEOSA-N NC(O[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O Chemical compound NC(O[C@@H]([C@@H](CC(C1)=NOC11CCCCC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1)=O DKEFKZPBIMPYER-BJKUESEOSA-N 0.000 claims description 2
- GYYLGHTUPKIANF-MPCSADPFSA-N OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1O Chemical compound OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1O GYYLGHTUPKIANF-MPCSADPFSA-N 0.000 claims description 2
- PCWUIKBPXNWJIY-PGEXYDAJSA-N OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1OCC(F)F Chemical compound OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1OCC(F)F PCWUIKBPXNWJIY-PGEXYDAJSA-N 0.000 claims description 2
- UEMNPBATOBHIIG-PGEXYDAJSA-N OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1OCC(O)=O Chemical compound OC[C@H]([C@@H]([C@@H]1N2N=NC(C(C=C3F)=CC(F)=C3F)=C2)O)O[C@H](CC(C2)=NOC22CCCCC2)[C@@H]1OCC(O)=O UEMNPBATOBHIIG-PGEXYDAJSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 2
- VZEOIIGXIMZHJW-UHFFFAOYSA-N OCC1OCC(C(C1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC Chemical compound OCC1OCC(C(C1O)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC VZEOIIGXIMZHJW-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 59
- 108010001517 Galectin 3 Proteins 0.000 abstract description 32
- 102000000802 Galectin 3 Human genes 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- 239000002904 solvent Substances 0.000 description 40
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 37
- 239000000243 solution Substances 0.000 description 34
- 206010012812 Diffuse cutaneous mastocytosis Diseases 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 102100039558 Galectin-3 Human genes 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000011321 prophylaxis Methods 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 238000010828 elution Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 102000007563 Galectins Human genes 0.000 description 13
- 108010046569 Galectins Proteins 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 11
- 206010019280 Heart failures Diseases 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 208000019425 cirrhosis of liver Diseases 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 239000012156 elution solvent Substances 0.000 description 11
- 238000007429 general method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 206010020772 Hypertension Diseases 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 201000009594 Systemic Scleroderma Diseases 0.000 description 9
- 206010042953 Systemic sclerosis Diseases 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 208000005069 pulmonary fibrosis Diseases 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 206010018364 Glomerulonephritis Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 208000017169 kidney disease Diseases 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229910004298 SiO 2 Inorganic materials 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 5
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
- 208000033679 diabetic kidney disease Diseases 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 206010072877 Intestinal fibrosis Diseases 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 150000002118 epoxides Chemical class 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000001117 keloid Anatomy 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- XUXVBCRAFCKDPP-UHFFFAOYSA-N CC(=O)OC1COCC(C1)OC(C)=O Chemical compound CC(=O)OC1COCC(C1)OC(C)=O XUXVBCRAFCKDPP-UHFFFAOYSA-N 0.000 description 3
- 101100054570 Caenorhabditis elegans acn-1 gene Proteins 0.000 description 3
- 208000032544 Cicatrix Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010050207 Skin fibrosis Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010044715 asialofetuin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000009787 cardiac fibrosis Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000006334 interstitial nephritis Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010014612 Encephalitis viral Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 101001042451 Homo sapiens Galectin-1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- FZENGILVLUJGJX-IHWYPQMZSA-N (Z)-acetaldehyde oxime Chemical compound C\C=N/O FZENGILVLUJGJX-IHWYPQMZSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- PLXDWEOBBCYSNK-LIEJCIORSA-N 2-[(4aR,6R,7R,8R,8aR)-7-methoxy-2,2-dimethyl-8-[4-(3,4,5-trifluorophenyl)triazol-1-yl]-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]acetaldehyde Chemical compound CO[C@@H]1[C@H]([C@H]2OC(OC[C@H]2O[C@@H]1CC=O)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F PLXDWEOBBCYSNK-LIEJCIORSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 1
- SIKSVZKBVFIJAK-UHFFFAOYSA-N 4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-7-ol Chemical compound O1COCC2C1CC(CO2)O SIKSVZKBVFIJAK-UHFFFAOYSA-N 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BZXWRVPVZZZAKB-UHFFFAOYSA-N 5-ethynyl-1,2,3-trifluorobenzene Chemical compound FC1=CC(C#C)=CC(F)=C1F BZXWRVPVZZZAKB-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002889 Aortic aneurysms and dissections Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010054793 Arterial fibrosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005042 Bladder fibrosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- YGIRDZKSCBIKLA-ZJXIFLPPSA-N C(C)(=O)O[C@@H]1[C@H]([C@H]2OC(OC[C@H]2O[C@@H]1CC=O)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F Chemical compound C(C)(=O)O[C@@H]1[C@H]([C@H]2OC(OC[C@H]2O[C@@H]1CC=O)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F YGIRDZKSCBIKLA-ZJXIFLPPSA-N 0.000 description 1
- YOJVGRXWBSKSAN-JKMASCRWSA-N CC(C)(C)OC(NC1(CNC[C@H]([C@@H]([C@H]2N3N=NC(C(C=CC(C)=C4F)=C4F)=C3)OC)O[C@H]3[C@@H]2OC(C)(C)OC3)CCCCC1)=O Chemical compound CC(C)(C)OC(NC1(CNC[C@H]([C@@H]([C@H]2N3N=NC(C(C=CC(C)=C4F)=C4F)=C3)OC)O[C@H]3[C@@H]2OC(C)(C)OC3)CCCCC1)=O YOJVGRXWBSKSAN-JKMASCRWSA-N 0.000 description 1
- LBQAQCZPRZYKLR-XDOCFNAUSA-N CC(C)(C)[Si](C)(C)O[C@@H]([C@@H](CC=NO)O[C@H]1[C@@H]2OC(C)(C)OC1)[C@H]2N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]([C@@H](CC=NO)O[C@H]1[C@@H]2OC(C)(C)OC1)[C@H]2N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 LBQAQCZPRZYKLR-XDOCFNAUSA-N 0.000 description 1
- ZNJBHUPNQNLTNV-XDOCFNAUSA-N CC(C)(C)[Si](C)(C)O[C@@H]([C@@H](CC=O)O[C@H]1[C@@H]2OC(C)(C)OC1)[C@H]2N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]([C@@H](CC=O)O[C@H]1[C@@H]2OC(C)(C)OC1)[C@H]2N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 ZNJBHUPNQNLTNV-XDOCFNAUSA-N 0.000 description 1
- XVRQFVWJOACNGH-JGOTUQMDSA-N CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CNCC3(CCCCC3)N)O)[C@H]2OC)N=N1)=C1F)=C1F Chemical compound CC(C=CC(C1=CN([C@@H]([C@H]([C@@H](CO)O[C@@H]2CNCC3(CCCCC3)N)O)[C@H]2OC)N=N1)=C1F)=C1F XVRQFVWJOACNGH-JGOTUQMDSA-N 0.000 description 1
- ICLVGBYTFAWGOV-XJGQCGLHSA-N CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1NC1CC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 Chemical compound CO[C@@H]([C@@H](CC(C1)=NOC1(CC1)CCC1NC1CC1)O[C@H](CO)[C@@H]1O)[C@H]1N1N=NC(C(C=C2F)=CC(F)=C2F)=C1 ICLVGBYTFAWGOV-XJGQCGLHSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102100025614 Galectin-related protein Human genes 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 description 1
- 101001004750 Homo sapiens Galectin-related protein Proteins 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- QWPXVLLZOIRZCN-XQZMSQOBSA-N N(=[N+]=[N-])C[C@@H]1[C@@H]([C@H]([C@H]2OC(OC[C@H]2O1)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC Chemical compound N(=[N+]=[N-])C[C@@H]1[C@@H]([C@H]([C@H]2OC(OC[C@H]2O1)(C)C)N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC QWPXVLLZOIRZCN-XQZMSQOBSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000006288 Vascular Tissue Neoplasms Diseases 0.000 description 1
- 208000012634 Venoocclusive liver disease Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007295 Wittig olefination reaction Methods 0.000 description 1
- ILOBAQYQYLYANO-MPCSADPFSA-N [(2R,3R,4R,5R,6R)-3,5-diacetyloxy-6-(2-oxoethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxan-2-yl]methyl acetate Chemical compound C(C)(=O)O[C@H]1[C@H](O[C@@H]([C@@H]([C@H]1N1N=NC(=C1)C1=CC(=C(C(=C1)F)F)F)OC(C)=O)CC=O)COC(C)=O ILOBAQYQYLYANO-MPCSADPFSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001361 allenes Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000012912 hepatic vascular disease Diseases 0.000 description 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- FGNGTWFJQFTFGN-UHFFFAOYSA-N n,n,n',n'-tetramethylethane-1,2-diamine Chemical compound CN(C)CCN(C)C.CN(C)CCN(C)C FGNGTWFJQFTFGN-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000006772 olefination reaction Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- MMQYUDBFDDEJBP-UHFFFAOYSA-N oxane-3,5-diol Chemical compound OC1COCC(O)C1 MMQYUDBFDDEJBP-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZIKUKJDGNXNBEU-UHFFFAOYSA-N tert-butyl n-(1-formylcyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1(C=O)CCCCC1 ZIKUKJDGNXNBEU-UHFFFAOYSA-N 0.000 description 1
- XXPQEMPUOHHFNE-UHFFFAOYSA-N tert-butyl n-[(1-formylcyclohexyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1(C=O)CCCCC1 XXPQEMPUOHHFNE-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- HYWCXWRMUZYRPH-UHFFFAOYSA-N trimethyl(prop-2-enyl)silane Chemical compound C[Si](C)(C)CC=C HYWCXWRMUZYRPH-UHFFFAOYSA-N 0.000 description 1
- ULYLMHUHFUQKOE-UHFFFAOYSA-N trimethyl(prop-2-ynyl)silane Chemical compound C[Si](C)(C)CC#C ULYLMHUHFUQKOE-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2020077968 | 2020-10-06 | ||
| EPPCT/EP2020/077968 | 2020-10-06 | ||
| PCT/EP2021/077381 WO2022073969A1 (en) | 2020-10-06 | 2021-10-05 | Spiro derivatives of alpha-d-galactopyranosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230083301A true KR20230083301A (ko) | 2023-06-09 |
Family
ID=78049262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237014525A Pending KR20230083301A (ko) | 2020-10-06 | 2021-10-05 | 알파-d-갈락토피라노사이드의 스피로 유도체 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12312362B2 (https=) |
| EP (1) | EP4225752B1 (https=) |
| JP (1) | JP7757399B2 (https=) |
| KR (1) | KR20230083301A (https=) |
| CN (1) | CN116348463A (https=) |
| AU (1) | AU2021356076A1 (https=) |
| CA (1) | CA3194831A1 (https=) |
| ES (1) | ES3014851T3 (https=) |
| IL (1) | IL301815A (https=) |
| MX (1) | MX2023004033A (https=) |
| TW (1) | TWI890869B (https=) |
| WO (1) | WO2022073969A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) * | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| CA3025867A1 (en) | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| EP3621973A4 (en) | 2017-05-12 | 2021-10-27 | Galectin Sciences, LLC | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3080128A1 (en) | 2017-10-31 | 2019-05-09 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| JP2022508720A (ja) | 2018-10-15 | 2022-01-19 | ガレクト バイオテック エービー | ガレクチンのガラクトシド阻害剤 |
| CN113286632A (zh) | 2018-10-15 | 2021-08-20 | 格莱克特生物技术公司 | 半乳糖凝集素的半乳糖苷抑制剂前药 |
| WO2020104335A1 (en) * | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CA3122321A1 (en) * | 2018-12-27 | 2020-07-02 | Glycomimetics, Inc. | Galectin-3 inhibiting c-glycosides |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
| RS67032B1 (sr) | 2021-03-03 | 2025-08-29 | Idorsia Pharmaceuticals Ltd | Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom |
-
2021
- 2021-10-05 US US18/248,007 patent/US12312362B2/en active Active
- 2021-10-05 CN CN202180068666.9A patent/CN116348463A/zh active Pending
- 2021-10-05 EP EP21785913.1A patent/EP4225752B1/en active Active
- 2021-10-05 WO PCT/EP2021/077381 patent/WO2022073969A1/en not_active Ceased
- 2021-10-05 TW TW110136996A patent/TWI890869B/zh active
- 2021-10-05 JP JP2023521100A patent/JP7757399B2/ja active Active
- 2021-10-05 ES ES21785913T patent/ES3014851T3/es active Active
- 2021-10-05 CA CA3194831A patent/CA3194831A1/en active Pending
- 2021-10-05 AU AU2021356076A patent/AU2021356076A1/en active Pending
- 2021-10-05 MX MX2023004033A patent/MX2023004033A/es unknown
- 2021-10-05 IL IL301815A patent/IL301815A/en unknown
- 2021-10-05 KR KR1020237014525A patent/KR20230083301A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023004033A (es) | 2023-04-27 |
| AU2021356076A9 (en) | 2024-10-17 |
| IL301815A (en) | 2023-06-01 |
| JP2023545046A (ja) | 2023-10-26 |
| US20230295182A1 (en) | 2023-09-21 |
| TWI890869B (zh) | 2025-07-21 |
| CA3194831A1 (en) | 2022-04-14 |
| ES3014851T3 (en) | 2025-04-25 |
| US12312362B2 (en) | 2025-05-27 |
| EP4225752B1 (en) | 2024-12-11 |
| JP7757399B2 (ja) | 2025-10-21 |
| EP4225752A1 (en) | 2023-08-16 |
| TW202222312A (zh) | 2022-06-16 |
| WO2022073969A1 (en) | 2022-04-14 |
| CN116348463A (zh) | 2023-06-27 |
| AU2021356076A1 (en) | 2023-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4225752B1 (en) | Spiro derivatives of alpha-d-galactopyranosides | |
| US12291520B2 (en) | Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| KR102863667B1 (ko) | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 | |
| JP7612662B2 (ja) | （ヘテロ）アリール－メチル－チオ－ベータ－ｄ－ガラクトピラノシド誘導体 | |
| EP4291556B1 (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| AU2020329609A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| HK40097240B (en) | Spiro derivatives of alpha-d-galactopyranosides | |
| HK40097240A (en) | Spiro derivatives of alpha-d-galactopyranosides | |
| EA048269B1 (ru) | Спиропроизводные альфа-d-галактопиранозидов | |
| HK40101885B (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| HK40101885A (en) | Hydroxyheterocycloalkane-carbamoyl derivatives | |
| EA050798B1 (ru) | 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3 | |
| EA048927B1 (ru) | Гидроксигетероциклоалканкарбамоильные производные |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230427 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240930 Comment text: Request for Examination of Application |